Please login to the form below
177Lu-PSMA-617
This page shows the latest 177Lu-PSMA-617 news and features for those working in and with pharma, biotech and healthcare.
Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
mCRPC patients treated with Lu-PSMA-617 plus best standard of care achieved a 38% reduction in the risk of death. ... This] data from the first phase 3 study of a radioligand therapy in this advanced prostate cancer setting confirm[s] the potential of
Latest news
-
Novartis bolsters radioligand therapy pipeline with new licence agreement
In this trial, 177Lu-PSMA-617 met the primary endpoints of overall survival and radiographic progression-free survival, with significant improvements on both these markers. ... For example, 177Lu-PSMA-617 binds to prostate cancer cells that express PSMA
-
Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer
Novartis’ investigational radioligand therapy 177Lu-PSMA-617 hit both primary endpoints in a phase 3 trial in patients with advanced prostate cancer. ... 177Lu-PSMA-617 is a type of precision medicine that combines a targeting compound – ligand –
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Endocyte’s lead clinical product is 177Lu‐PSMA‐617, which uses its proprietary drug conjugation technology to deliver Lutetium‐177 directly to tumours. ... the TRiM platform, for chronic HBV infection. Licence. $3.7B. Endocyte /. Novartis.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- How an AI algorithm might save your life
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
fox&cat
Fox&cat is a new kind of fully-integrated communications agency – one that delivers genuinely inspirational campaigns and programmes with equal...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
